# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sugar Ray Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-BX003-SYN
- Date: 2026-07-07
- Fictional facility: St. Posthumous Health Center
- Fictional author: Langston Pryce-Okonjo, MD
- Calendar frame: modern shifted

## What we are working on

- He wants to know why he is forgetting and what can be done **S**
- He wants to keep his independence and keep working with the young fighters at the foundation **S**
- His care partner is worried about his driving and about managing alone **S**

## Your goals

- Find the cause of the memory loss and explain it to him in a way he can take in. Target: 2026-08-18. Recorded outcome: Alzheimer's disease confirmed by amyloid PET; disclosed with his care partner present, at his request, with written notes. **S**
- No hypoglycemia, with hemoglobin A1c under 8.0%. Target: 2026-10-27. Recorded outcome: Glipizide stopped after one reading of 68 mg/dL; no low readings since; A1c 6.4 to 6.9%. **S**
- Stay safe: no driving and no firearm in the home. Target: 2026-08-18. Recorded outcome: He stopped driving and the handgun was removed from the home. **S**
- Keep his days full and give his care partner regular breaks. Target: 2026-10-27. Recorded outcome: Adult day program two days a week; walks and the foundation gym on other days; Alzheimer's Association helpline. **S**

## What we agreed to do

- Dementia work-up under the Alzheimer's Association guideline: history from him and his care partner, MoCA, function, depression screening, first-tier blood tests (blood count, metabolic panel, B12, TSH), a review of medicines for anticholinergic and sedating drugs, a sleep apnea screen, and brain MRI. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026) **S**
- Cognitive neurology consultation at the memory clinic to stage the dementia, weigh Alzheimer's disease against traumatic encephalopathy syndrome and vascular disease, choose biomarker testing, and decide anti-amyloid eligibility. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025); National Institute of Neurological Disorders and Stroke Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (2021) **S**
- Stop diphenhydramine, a strongly anticholinergic sleep aid; sleep habits and morning light instead. Guideline: American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults (2023) **S**
- Driving: no driving until the evaluation is complete, with his care partner driving; firearm: unloaded and locked, with the key held by his care partner, until a decision with him. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Practice Parameter update: Evaluation and management of driving risk in dementia (2010) **S**
- Amyloid PET to confirm Alzheimer's disease pathology; APOE genotyping not needed because he is not a candidate for anti-amyloid therapy, and offered only with counseling. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Lecanemab: Appropriate Use Recommendations (2023); Donanemab: Appropriate use recommendations (2025) **S**
- Donepezil 5 mg at bedtime with a baseline ECG and pulse checks, raised to 10 mg after four to six weeks if tolerated; taken in the morning if dreams are vivid. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026) **S**
- Diabetes deintensified under the ADA Standards for older adults: stop glipizide, continue metformin, hemoglobin A1c goal under 8.0%, sick-day rules (hold metformin when not eating or drinking), and B12 checked periodically. Guideline: CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**
- Blood pressure under 130/80 mmHg on lisinopril, with potassium and creatinine checks. Guideline: CMID: Clinical Monitoring Intelligence Database, Alzheimer's disease, diabetes type 2 and hypertension monographs (2026); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**
- Hearing aids for both ears, fitted by the audiologist. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024) **S**
- Stop driving after the diagnosis (CDR 1 and getting lost), with transport planned; the handgun removed from the home. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Practice Parameter update: Evaluation and management of driving risk in dementia (2010) **S**
- Caregiver support: education, the Alzheimer's Association 24/7 Helpline, an adult day program for respite, a caregiver burden check, and the Medicare GUIDE dementia care model once he has Medicare. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); Guiding an Improved Dementia Experience (GUIDE) Model (2024) **S**
- Advance care planning while he can take part fully: a health care agent and his values, at the preventive visit. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024) **S**
- Exercise, social activity and diabetes and blood pressure control as the brain-health measures with the most support. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for specialty care (2024); 13. Older Adults: Standards of Care in Diabetes-2026 (2026) **S**

## Follow-up

- 2026-07-07: Establishing care for memory loss and getting lost, with his care partner: cognitive testing, reversible causes, medicines, diabetes and blood pressure, driving and firearm safety **S**
- 2026-07-21: Two-week review, seen the same day by cognitive neurology: brain MRI, hearing test, staging, Alzheimer's disease against traumatic encephalopathy syndrome, and anti-amyloid eligibility **S**
- 2026-08-18: Six-week review: amyloid PET result, the diagnosis and the plan, with diabetes, driving, firearm and caregiver support **S**
- 2026-09-08: Periodic adult preventive visit **S**
- 2026-09-22: Eleven-week review: donepezil dose, diabetes, hearing aids and day program **S**
- 2026-10-27: Sixteen-week review: medicines, kidneys, mood, caregiver strain and the plan **S**

This teaching document does not replace care from a qualified clinician.
